AXA Framlington Biotech Fund - Z Accumulation

Category Sector Equity Biotechnology

This fund can be held in an Investment ISA, SIPP and Investment Account

Last buy/sell price

566.10p

arrow-down-10.00p (-1.74%)

Fund Code

FMBTA

B784NS1

GB00B784NS11

Prices updated as at 13 Nov 2024

Prices in GBX

Investment objective

The aim of this Fund is to provide long-term capital growth over a period of 5 years or more. The Fund invests in shares of listed companies, principally in the biotechnology, genomic and medical research industry, which the Manager believes will provide above-average returns. The Fund invests in companies of any size which can be based anywhere in the world, albeit the Fund tends to be biased towards the US as this is where the majority of biotechnology companies are based. The Manager selects shares based upon analysis of a company’s financial status, quality of its management, expected profitability and prospects for growth.

Important documents: Please ensure that you have read the Key Information Document/Technical Guide , Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and the fund information documents. These can be found within the Charges & documents section.

Fund status	Open
Fund type	Unit Trust
Fund manager	Chris Eccles, Cinney Zhang, Catherine Tennyson
	586
	440.5
Fund comparative index	NASDAQ Biotechnology TR USD
	Specialist
	-
	0.80
	0.35
	0.00
	Sector Equity Biotechnology
	No
Fund provider	AXA Investment Managers UK Ltd
Share class launch date	16 Apr 2012
	£399.52m
	-
	0.00
	-
	Semi-Annually

Please note that some funds may have small additional incidental charges that are not shown here. Where these charges do exist they are included within the variable ongoing costs in the Pre-sale Illustration.

Important Information

Please note the value of investments can go down as well as up so you may get back less than you invested. This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to an authorised financial adviser. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and(3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.

Any ESG-related information, methodologies, tools, ratings, data and opinions contained or reflected herein are not directed to or intended for use or distribution to India-based clients or users and their distribution to Indian resident individuals or entities is not permitted, and Morningstar accepts no responsibility or liability whatsoever for the actions of third parties in this respect.